HR
IBRX icon

Howe & Rusling’s ImmunityBio IBRX Stock Holding History

Howe & Rusling’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50
Closed – – 917
2017
Q2 		$0 Hold
50
– – ﹤0.01% 983
2017
Q1 		$0 Hold
50
– – ﹤0.01% 1025
2016
Q4 		$0 Hold
50
– – ﹤0.01% 1052
2016
Q3 		$0 Hold
50
– – ﹤0.01% 1075
2016
Q2 		$0 Hold
50
– – ﹤0.01% 997
2016
Q1 		$0 Hold
50
– – ﹤0.01% 1024
2015
Q4 		$1K Hold
50
– – ﹤0.01% 909
2015
Q3 		$1K Buy
+50
New +$1.09K ﹤0.01% 917

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Howe & Rusling's IBRX Position: Q3 2017 in Review

Howe & Rusling sold out of ImmunityBio (IBRX) in Q3 2017, closing a stake of 50 shares.

Howe & Rusling first reported a position in IBRX in Q3 2015 and held it in 8 quarters. The position peaked at $1K in Q4 2015. 57 funds tracked by Wall St. Rank hold IBRX as of Q3 2017.

  • Howe & Rusling reported no remaining ImmunityBio position as of Q3 2017 after selling out during the quarter.
  • Howe & Rusling sold 50 ImmunityBio shares in Q3 2017.
  • Howe & Rusling first reported a position in ImmunityBio in Q3 2015 and held it in 8 quarters.
  • Howe & Rusling's ImmunityBio position peaked at $1K in Q4 2015.
  • 57 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2017.

Based on Howe & Rusling's 13F filing for Q3 2017, filed 18 Oct 2017.